Rosuvastatin is a potent statin.

Biochemical, histopathological, ultrastructural analysis and functional tests revealed that rosuvastatin exhibits meaningful neuroprotection effects against spinal cord injury ¹⁾.

Rosuvastatin pretreatment ameliorates early brain injury (EBI) after a subarachnoid hemorrhage (SAH) through the attenuation of oxidative stress and nuclear factor-kappa B (NF-κB) mediated inflammation ²⁾.

Both topical application and systemic administration of ROS show meaningful preventive effects over epidural fibrosis through multiple mechanisms. The results of a study provide the first experimental evidence of the preventive effects of ROS over epidural fibrosis ³⁾

Rosuvastatin promoted endothelialization of the coiled aneurysm neck via induction of endothelial progenitor cells (EPCs), suggesting that promoting endothelialization provides an additional therapeutic opportunity during vascular endothelium repair ⁴⁾